MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib for leukaemia and other haematologic malignancies after eDMC review.
The post MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib appeared first on Clinical Trials Arena .